Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL

 Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL

Roche Receives EU Approval for Venclyxto (venetoclax) plus MabThera (rituximab) to Treat Adults with CLL

Shots:

  • The approval is based on the results of P-III MURANO study assessing Venclexta + MabThera (six cycles) vs (bendamustine + MabThera) (BR) (six cycles) in 389 patients in ratio (1:1) with 1L r/r CLL for two years
  • P-III MURANO study results: mPFS 83%; no. of events (32 vs 114); ORR (93.3% vs 67.7%); CR/CRi (26.8% vs 8.2%); MRD-negativity in peripheral blood, bone marrow (62.5%, 15.5% vs 13.3%,1.0%)
  • Venclyxto is a novel inhibitor of B-cell lymphoma-2 (BCL-2) protein, developed by Roche & AbbVie and is currently approved in 50 countries

Click here to read full press release/ article | Ref: Roche | Image: Fortune

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post